Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Research Report 2024
According to MRAResearch’s new survey, global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is projected to reach US$ 24730 million in 2033, increasing from US$ 9591.9 million in 2022, with the CAGR of 14.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market research.
Key companies engaged in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry include Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
Segment by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Key companies engaged in the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry include Qiagen NV, GE Healthcare, Agilent Technologies, F Hoffman La Roche, Foundation Medicine, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH and Pfizer, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Qiagen NV
GE Healthcare
Agilent Technologies
F Hoffman La Roche
Foundation Medicine
Thermo Fisher Scientific Inc.
Leica Biosystems Nussloch GmBH
Pfizer
Segment by Type
PCR
In-situ Hybridization
Immunohistochemistry
Sequencing
Others
Segment by Application
Oncology
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices